Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài:Hypersensitivity reaction and acute immunemediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature | Bautista et al. Journal of Hematology Oncology 2010 3 12 http content 3 1 12 JOURNAL OF HEMATOLOGY ONCOLOGY CASE REPORT Open Access Hypersensitivity reaction and acute immune-mediated thrombocytopenia from oxaliplatin two case reports and a review of the literature 1 1 2 3 34 2 Marnelli A Bautista W Tait Stevens Chien-Shing Chen Brian R Curtis Richard H Aster Chung-Tsen Hsueh Abstract Background Oxaliplatin is a platinum compound used in the treatment of gastrointestinal malignancies including colorectal cancer. The incidence of hypersensitivity reaction in patients receiving oxaliplatin is approximately 15 with severe reaction grade 3 and 4 occurring in 2 of patients. Case presentation We report two patients with metastatic colorectal cancer who developed de novo hypersensitivity reaction and acute thrombocytopenia after oxaliplatin infusion. Both patients had oxaliplatin treatment several years before and exhibited hypersensitivity on the third dose of oxaliplatin in recent treatment. Oxaliplatin was discontinued when clinical reaction was identified. Both patients were confirmed to have strong oxaliplatin-induced IgG platelet-reactive antibodies. Both patients thrombocytopenia resolved within two weeks after discontinuation of oxaliplatin. One patient had disease stabilization lasting for three months without chemotherapy. Both patients subsequently received other chemotherapeutic agents without evidence of hypersensitivity reaction or immune-mediated thrombocytopenia. Conclusion We recommend vigilant monitoring of complete blood count and signs and symptoms of bleeding after the occurrence of oxaliplatin-induced hypersensitivity to avoid serious complications of immune-mediated thrombocytopenia. Background Oxaliplatin is a third-generation platinum derivative that has been widely used in patients with gastrointestinal malignancies including colorectal cancer CRC . The combination of 5-fluorouracil leucovorin and oxaliplatin FOLFOX has been .
